Kenneth Attie
Vice Presiden- Clinical Research & Obesity Eli Lilly & Co.
Seminars
Wednesday 15th July 2026
Body Composition Changes During Withdrawal from Weight Loss Medications: Insights from the BELIEVE Trial Extension and Metabolic Implications
2:00 pm
- Comparing semaglutide and bimagrumab, alone or in combination, during 72 weeks treatment and 32 weeks withdrawal to understand actual changes in fat and lean mass by serial DXA measurements
- Quantifying differential effects on visceral fat, subcutaneous fat, and skeletal muscle of incretins and activin pathway inhibitors • Implications for durable vs pharmacologic effects on adipose, muscle, and other tissues and the long-term cardio-metabolic consequences
- Incorporating follow-on studies to track the durability of benefits associated with various weight loss mechanisms and treatment strategies.
